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Hemorrhage remains a major cause of potentially preventable deaths. Trauma and massive transfusion are
associated with coagulopathy secondary to tissue injury, hypoperfusion, dilution, and consumption of clotting
factors and platelets. Concepts of damage control surgery have evolved prioritizing early control of the cause of
bleeding by non-definitive means, while hemostatic control resuscitation seeks early control of coagulopathy.
Hemostatic resuscitation provides transfusions with plasma and platelets in addition to red blood cells in an
immediate and sustained manner as part of the transfusion protocol for massively bleeding patients. Although early
and effective reversal of coagulopathy is documented, the most effective means of preventing coagulopathy of
massive transfusion remains debated and randomized controlled studies are lacking.
Viscoelastical whole blood assays, like TEG and ROTEM however appear advantageous for identifying coagulopathy
in patients with severe hemorrhage as opposed the conventional coagulation assays.
In our view, patients with uncontrolled bleeding, regardless of it´s cause, should be treated with hemostatic control
resuscitation involving early administration of plasma and platelets and earliest possible goal-directed, based on the
results of TEG/ROTEM analysis. The aim of the goal-directed therapy should be to maintain a normal hemostatic
competence until surgical hemostasis is achieved, as this appears to be associated with reduced mortality.
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antifibrinolyticsIntroduction
Hemorrhage requiring massive transfusion remains a major
cause of potentially preventable deaths. Trauma and
massive transfusion are associated with coagulopathy sec-
ondary to tissue injury, hypoperfusion, dilution and con-
sumption of clotting factors and platelets and coagulopathy,
together with hypothermia and acidosis, forms a “lethal”
triad [1]. Also, in the last 10–15 years there has been some
paradigm shift regarding optimal resuscitation of bleeding
trauma patients before definitive hemorrhage control is
achieved. Aggressive fluid resuscitation increases blood
pressure, reverses vasoconstriction, dislodges early formed
thrombus, causes dilutional coagulopathy and metabolic
acidosis and increases blood loss in experimental studies
[2]. Accordingly previous guidelines [3] recommending that* Correspondence: per.johansson@rh.regionh.dk
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distribution, and reproduction in any mediumfresh frozen plasma (FFP) and platelets (PLT) should be
administered only when a whole blood volume or more has
been substituted and then according to conventional coagu-
lation analyses is now considered obsolete since this strat-
egy leads to dilutional coagulopathy and compromises
hemostatic competence in the most severely bleeding
patients [1]. Instead, limiting fluid resuscitation and apply-
ing the concept of permissive hypotension with the goal of
achieving a palpable radialis pulse in patients has been
advocated, whereas in patients with head injury a systolic
blood pressure above 110 mmHg is recommended [4-7].
The current transfusion guidelines advocate the concept
of hemostatic control resuscitation, i.e., supplementing large
transfusions of red blood cells (RBC) with FFP and PLT to
critically injured patients in an immediate and sustained
manner is proposed [7-9]. The rationale for balanced ad-
ministration of blood products is that it mimics the com-
position of circulating blood and, hence, transfusion of
RBC, FFP and PLT in a unit-for-unit ratio is likely to both
prevent and treat coagulopathy due to massive hemorrhage.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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hemorrhage and massive transfusion in trauma.Coagulopathy in massive hemorrhage
Dilution
The dilution of coagulation factors and platelets is an im-
portant cause of coagulopathy in massively transfused
trauma patients [10]. The Advanced Trauma Life Support
guideline recommends aggressive crystalloid resuscitation
but the dilutional effects of such administration on coagu-
lation competence are well described [11,12] and this strat-
egy provokes acidosis, formation of interstitial oedema
with tissue swelling, impairment of the microcirculation
and hence compromised oxygenation [13,14].
Furthermore, synthetic colloid resuscitation fluids influ-
ence coagulation competence more profoundly than crys-
talloids. Hydroxyethyl starch (HES) causes efflux of plasma
proteins from blood to the interstitial space, reduction in
plasma concentration of coagulation factor VIII and von
Willebrand factor (vWF), inhibition of platelet function and
reduced interaction of activated FXIII with fibrin polymers
[11,12,15].. This was further corroborated by a recent meta-
analysis of 24 studies evaluating the safety of HES 130/0.4
administration in surgical, emergency and intensive care
patients, with results demonstrating that HES administra-
tion promotes a dose-dependent coagulopathy [16]. Also,
administration of blood products such as RBC, FFP and
PLT may cause significant dilution since these blood pro-
ducts are stored in anticoagulation solutions reducing co-
agulation factor concentration to approximately 60% and
platelet count to approximately 80x109/l when a hematocrit
of 30% is warranted [17].Hypothermia
Hypothermia is associated with risk of uncontrolled bleed-
ing and death in trauma patients. Hypothermia induced
coagulopathy is attributed to platelet dysfunction, reduced
coagulation factor activity (significant below 33°C) [14,18],
and induction of fibrinolysis [19] and these effects are re-
versible with normalization of body temperature.Acidosis
In trauma patients acidosis is often induced by hypoperfu-
sion and excess administration of ionic chloride, i.e. NaCl
during resuscitation [20]. Acidosis impairs almost all es-
sential parts of the coagulation process: At pH < 7.4, pla-
telets change their structure and shape [21]. The activity
of coagulation factor complexes on the cell surface is
reduced and the resulting impaired thrombin generation
is a major cause of coagulopathic bleeding. Furthermore,
acidosis leads to increased degradation of fibrinogen [22]
which further aggravates the coagulopathy.Trauma
Brohi et al. [23-27] described an early “endogenous” coagu-
lopathy in trauma patients not attributed to dilution and
hypothermia with shock and hypoperfusion as the key dri-
vers of acute traumatic coagulopathy through widespread
activation of the anticoagulant and fibrinolytic pathways.
We recently suggested that the coagulopathy observed in
trauma patients, which reflects the state of the fluid phase
including its cellular elements i.e., circulating whole blood,
is a consequence of the degree of the tissue injury and the
thereby generated sympathoadrenal activity and import-
antly, critically related to the degree of endothelial damage,
with a progressively more procoagulant endothelium (solid
phase) inducing a gradient of increasing anticoagulation to-
wards the fluid phase (circulating blood) [28]. Though it
seems counterintuitive that increasing injury severity is
associated with progressive hypocoagulability and hyperfi-
brinolysis [28,29], this may from an evolutionary perspec-
tive exert a survival advantage by preserving blood flow
through the progressively more damaged and procoagulant
microvasculature [28] In alignment with this, we found that
in trauma patients upon hospital admission, a high level of
syndecan-1, a marker of endothelial glycocalyx degradation,
was associated with high sympathoadrenal activity and
increased mortality, even after adjusting for injury severity
score [30]. Also, only in patients with high syndecan-1
levels, was increasing injury severity associated with
increased tissue and endothelial damage, protein C deple-
tion, hyperfibrinolysis and inflammation [30].
Consumptive coagulopathy
Tissue injury secondary to trauma induce immediate activa-
tion of the coagulation system through upregulation of tissue
factor (TF) expression and extensive thrombin generation.
Tissue injury in association with extensive endothelial injury,
massive soft tissue damage, and fat embolization from long
bone fractures, may be associated with consumption of co-
agulation factors and platelets and, hence development of
coagulopathy. Disseminated intravascular coagulation (DIC)
is the most extreme form of consumptive coagulopathy and
is characterized by systemic activation of pathways leading
to and regulating coagulation, which can result in the gener-
ation of fibrin clots that may cause organ failure with con-
comitant consumption of platelets and coagulation factors
that may result in clinical bleeding [31,32]. We recently
reported that disseminated intravascular coagulation (DIC)
was not a part of the early coagulopathy secondary to
trauma [33] though this may develop later in the course of
resuscitation as described by Gando et al. [34].
Hyperfibrinolysis
Increased fibrinolysis is observed in patients with pro-
found endothelial activation and damage secondary to
trauma, surgery and ischemia-reperfusion injury where
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the Weibel-Palade bodies of the endothelial cells. In
trauma, increased fibrinolysis has been reported in the most
severely injured patients and this correlates with poor out-
come [29,35-38]. The presence of increased fibrinolysis with
increasing injury severity probably reflects an evolutionary
mechanism aiming at preventing fatal intravascular coagu-
lation secondary to systemic hypercoagulation induced by
the trauma, as reported recently by us [28].
Anticoagulation
Vitamin K antagonists are frequently used by patients with
atrial fibrillation or artificial cardiac valves and warfarin has
been reported to be associated with about 21,000 visits for
bleeding complications per year in the US alone [39], and
these data are consistent with reports of major bleeding
frequencies for warfarin as high as 10% to 16% [40]. The
use of International Normalized Ratio (INR, a plasmatic
coagulation analysis) to monitor the degree of anticoagula-
tion by warfarin may in part explain this problem. The lack
of adequate hemostatic monitoring is also evident with
regards to the newer pharmaceutical agents used for sec-
ondary prevention and postoperative thromboprophylaxis
such as the direct thrombin inhibitor dabigatran [41], the
indirect FXa inhibitors apixaban [42] and rivaroxaban [43].
Furthermore, as for now it is recommended that treatment
with these agents do not require hemostatic monitoring
[44]. Despite this, however, reports of severe bleedings in
patients taking these medications are being reported, in-
cluding trauma,and since no antidote exists treatment of
these patients is a major challenge [45].
Apart from coagulopathy due to iatrogenic heparinization,
critically ill patients, including trauma patients, may become
endogenously heparinized due to degradation of the endo-
thelial glycocalyx [30,46], the antiadhesive and anticoagulant
carbohydrate-rich surface layer that covers and protects the
endothelial cells and contains significant amounts of
heparin-like substances [47-53].
Platelet inhibitors
An important cause of excessive bleeding in trauma
patients is platelet inhibitors, which an increasing propor-
tion of the population today uses as secondary prevention.
Currently, the most important are the platelet ADP recep-
tor inhibitors clopidogrel and lately also the even more
potent prasugrel that irreversibly inhibits platelet activa-
tion through the platelet ADP receptor and confers more
potent platelet inhibition than acetylsalicylic acid
Importantly, the enhanced antiplatelet activity and
greater efficacy seen with prasugrel when compared to
clopidogrel in clinical trials has been accompanied by
increased bleeding risk and the FDA advisory committee
issued guidance to physicians about increased risk in
low-weight or elderly patients [54].Monitoring hemostasis
Whole blood viscoelastical assays
Introduction of the cell-based model of hemostasis empha-
sizes the role of platelets for intact thrombin generation
and highlights the importance of the dynamics of thrombin
generation influencing the quality and stability of the
thrombus formed [55]. Consequently, hemostatic assays
performed on plasma such as activated partial thrombo-
plastin time (APTT) and prothrombin time (PT) are of lim-
ited value [56] and they do not correlate with clinically
relevant coagulopathies [57,58]. Instead, employing a whole
blood assay, such as viscoelastic hemostatic assays (VHA)
like TEG/ROTEM that records the viscoelastic changes
during clot formation and subsequent lysis is preferable.
The TEG reports (Figure 1): R (reaction time), angle (α), the
maximum amplitude (MA), the maximal clot strength; and
clot lysis (Ly) [29,59-61]. Typical TEG profiles observed in
trauma patients are normal, hypercoagulable, hypocoagul-
able and hyperfibrinolytic profiles (Figure 2), and in actively
bleeding patients these are treated according to an algo-
rithm (Table 1).
Reduced clot stability correlates with clinical bleeding
conditions as demonstrated by Plotkin et al. [62] who, in
patients with a penetrating trauma, reported TEG to be an
accurate indicator of the blood product requirements. Fur-
thermore, TEG is the gold standard for identifying hyper-
coagulability [63-65] and hyperfibrinolysis [35-38,65,66], the
latter a significant cause of bleeding in patients with major
trauma [29,35-38,59-61,66]. The use of VHA in trauma is
now recommended by recent guidelines [67,68] and text
books [69] and its use in the military field is extensive and
many Level 1 trauma centers consider use of VHA to
monitor and guide hemostatic therapy as routine.
Whole blood platelet function analyzers
Different assays evaluating the degree of platelet inhibition
secondary to platelet inhibitors exists. Light transmission
aggregometry (LTA), previously considered the ”gold
standard” for investigation of platelet aggregation [70], un-
fortunately relies on artificially manufactured platelet rich
plasma suspensions, which do not reflect in vivo condi-
tions and consequently platelet function assays performed
on whole blood are today favored. Examples of whole
blood platelet function assays are PFA100 (Siemens, Tarry-
town, USA), VerifyNow (Accumetrics, San Diego, USA)
and Multiplate (Verum Diagnostica GmbH, Munich,
Germany), which all have been reported to be able to
identify clinically relevant platelet inhibition secondary to
pharmacological platelet inhibitors.
Goal-directed hemostatic resuscitation based on
VHA
Goal-directed treatment with blood products and antifi-








Ly / CLK / CFT
Figure 1 Schematic TEG/ROTEM trace indicating the commonly reported variables reaction time (R)/clotting time (CT), clot formation
time (K, CFT), alpha angle (α), maximum amplitude (MA)/maximum clot firmness (MCF) and lysis (Ly)/clot lysis (CL).
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together with the clinical presentation, was introduced for
more than 25 years ago in patients undergoing liver trans-
plantation and cardiac surgery and there are validated
algorithms for how coagulopathy is identified and treated
in patients with ongoing bleeding, based on VHA [71].
More than 25 studies encompassing more than 4,500
patients have evaluated VHA vs. conventional coagulation
assays on bleeding and transfusion requirements in
patients undergoing cardiac, liver, vascular, or trauma sur-
gery and in patients requiring massive transfusion. These
studies demonstrate the superiority of VHA in predicting
the need for blood transfusion, and the VHA-based algo-
rithm reduces the transfusion requirements and the need
for re-do surgery in contrast to treatment based on con-
ventional coagulation assays [29] and this was further cor-
roborated in a recent Cochrane review [72].
We found that implementation of goal-directed hemostatic
resuscitation of massively bleeding patients, including
trauma, based on the VHA reduced mortality by approxi-
mately 30% in patients requiring more than 10 RBC in the
first 24 hours [71]. Systematic use of VHA to monitor and




Figure 2 Schematic presentation of various VHA tracings: A) Normal,
deficiency and thrombocytopenia/pathy and/or low fibrinogen) and Dseveral recent international transfusion guidelines and
teaching books [68,69].Administration of blood products
Red blood cells
In response to hemorrhage, lowered hematocrit contri-
butes to coagulopathy since erythrocytes promote
marginalization of platelets so the platelet concentra-
tions along the endothelium remains almost seven times
that of the average blood concentration [73]. In addition,
erythrocytes support thrombin generation through ex-
posure of procoagulant membrane phospholipids [1,74]
and they activate platelets by liberating ADP [75,76] em-
phasizing that in vivo thrombus formation is a multicel-
lular event [55,77]. Yet, the optimal hematocrit for
platelet-vessel wall interactions remains unknown but it
may be as high as 35% [78].Fresh frozen plasma
It remains controversial when and in what dose plasma
should be transfused to massively bleeding trauma
patients[79-87].B) Hypercoagulability, C) Hypocoagulability (coagulation factor
) Primary hyperfibrinolysis.
Table 1 Recommended TEG algorithm for goal-directed therapy of bleeding patients in the Capital Region of Denmark
TEG parameter* Coagulopathy Intervention
R >10 min Coagulation factors # FFP 10–20 ml/kg (if FFP is without clinical efficacy,
consider cryoprecipitate 3–5 ml/kg)
Angle <52 ° Hypofibrinogenemia? ! Functional Fibrinogen (FF) analysis
MA <49 mm and
MAFF <14 mm Fibrinogen # FFP 20–30 ml/kg /
Fibrinogen konc. 25–50 mg/kg /
Cryoprecipitate 5 ml/kg
MA <49 mm and
MAFF >14 mm Platelets # Platelets 5–10 ml/kg
Ly30 >8% Primary hyperfibrinolysis Tranexamic acid 1–2 g IV (adults)
Children 10–20 mg/kg IV
Ly30 >8% and
Angle and/or MA "" Reactive hyperfibrinolysis Tranexamic acid contraindicated
Difference in R >2 min between st-TEG and hep-TEG Heparinization Protamine sulphate or FFP 20–30 ml/kg
R, Reaction time; Angle, α-angle; MA, Maximum amplitude; MAFF, Maximum amplitude by Functional Fibrinogen
W analysis; Ly30, Lysis after 30 min; st-TEG,
standard TEG; hep-TEG, heparinase TEG.
*Reference values (Haemonetics Corp.): R 3–8 min, Angle 55–78 °, MA 51–69 mm, Ly30 0-8%, MAFF=14-24 mm.
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lished although collectively the data indicate that a FFP:
RBC ratio greater than 1:2 is associated with improved
survival compared to one lower than 1:2 [79,80,83-85].
This is further supported by a review and meta-analysis
from 2010 reporting that in patients undergoing massive
transfusion, high FFP to RBC ratios was associated with
a significant reduction in the risk of death (odds ratio
(OR) 0.38 (95%CI 0.24-0.60) and multiorgan failure (OR
0.40 (95%CI 0.26-0.60) [88], and a meta-analysis from
2012 reports of reduced mortality in trauma patients
treated with the highest FFP or PLT to RBC ratios [89].Platelets
Platelets are also pivotal for hemostasis [55,77] and several
retrospective studies report an association between
thrombocytopenia and postoperative bleeding and mortal-
ity [8,90,91]. Holcomb et al. [85] found that the highest
survival was established in patients who received both a
high PLT:RBC and a high FFP:RBC ratio. Inaba et al. re-
cently reported from a retrospective study of massively
transfused patients that as the apheresis platelet to RBC
ratio increased, a stepwise improvement in survival was
seen and a high apheresis PLT:RBC ratio was independ-
ently associated with improved survival [92]. This is in
alignment with Brown et al. who reported that admission
platelet count was inversely correlated with 24-hour mor-
tality and transfusion of RBCs and that a normal platelet
count may be insufficient after severe trauma suggesting
these patients may benefit from a higher platelet transfu-
sion threshold [93]. In a recent meta-analysis, a high PLT:RBC ratio in massively bleeding trauma patients was
reported to reduce mortality [89].Massive transfusion protocols and ratios
A recent meta-analysis of retrospective observational stud-
ies evaluating the effect of FFP:RBC and/or PLT:RBC ratios
and survival in massively bleeding trauma patients recently
reported a significant survival benefit in patients receiving
high FFP:RBC and PLT:RBC ratios [89]. A potential con-
founder of these results are survivorship bias relating to
that those surviving long enough will receive FFP and PLT
whereas those dying early will not, as reported by Snyder
et al. [79]. This was recently corroborated by Ho et al. who
employed mathematical modeling of the observational
trauma studies performed involving FFP:RBC ratios con-
cluding that some of these probably included survivorship
bias in favor of a high FFP:RBC ratio [94].
Survivorship bias, however, does not explain the
improved survival in studies concerning the introduction
of transfusion packages where both FFP and PLT are im-
mediately available i.e. where pre-thawed FFP are available.
Cotton et al. [95] implemented a trauma exsanguination
protocol (TEP) involving 10 RBC, 4 FFP and 2 apheresis
PLT for trauma patients and used it to evaluate 211 trauma
patients of who 94 received TEP and 117 were historic
controls. The TEP patients received more RBC (16 vs. 11),
FFP (8 vs. 4), and PLT (2 vs. 1) intraoperatively than the
controls and displayed lower 30-day mortality (51% vs.
66%). After controlling for age, sex, mechanism of injury,
Trauma and Injury Severity Score (TRISS), and 24-hour
blood product usage, a 74% reduction in the odds ratio of
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later study involving additionally 53 patients
Cotton also [96] reported that not only was 30-day sur-
vival higher in the TEP group compared to the controls,
but the incidence of pneumonia, pulmonary failure and ab-
dominal compartment syndrome was lower in the TEP
patients. Also, the incidence of sepsis or septic shock and
multi-organ failure was lower in TEP patients. Although
the TEP group received more blood products intraopera-
tively, the 24 h transfusion requirements were lower than
in controls, supporting that early and aggressive adminis-
tration of plasma and platelets improves hemostasis and
this is in alignment with the result of a recent meta-
analysis of trauma patients requiring massive transfusion
[89]. In alignment with this, Duchesne et al. reported that
in trauma patients undergoing damage control laparotomy
introduction of damage control resuscitation encompass-
ing early administration of plasma and platelets together
with RBC was associated with improved 30-day survival,
(73.6% vs. 54.8%, p<0.009) when compared to patients
treated with conventional resuscitation efforts [97]. Simi-
larly, we evaluated 832 massively transfused patients, of
whom 20% were trauma patients, two years prior toand
two years after implementation of hemostatic control re-
suscitation in 2004 [71]. The concept involved pre-emptive
use of PLT and FFP organized into transfusion packages (5
RBC, 5 pre-thawed FFP and 2 PLT; each a pool of 4 buffy
coat platelets) to be administered to patients with uncon-
trollable bleeding. Compared to the controls, the interven-
tion group received displayed a reduction in 30-day
mortality (20% vs. 32% in controls, p=0.002).
A multicentre randomized control study evaluating the
effect of different blood product ratios on survival in mas-
sively bleeding trauma patients will commence in the USA
this year and hopefully this will result in evidence for how
best to resuscitate these patients with blood products
(http://www.uth.tmc.edu/cetir/PROPPR/index.html).
Fresh whole blood
With the implementation of fractionated blood compo-
nents, routine use of fresh whole blood (FWB) for resusci-
tation of bleeding patients was abandoned in the civilian
setting. In the combat setting, however, FWB has been
used in situations where fractionated blood products, and
especially platelets were not available. In a report of US
military patients in Iraq and Afghanistan from January
2004 to October 2007, those with hemorrhagic shock, a
resuscitation strategy that included FWB was associated
with improved 30-day survival (95% vs. 82%, p=0.002) [98]
and an ongoing trial is currently addressing this issue
(www.clingovtrial.com/ NCT01227005)..
It should be noted that administration of any blood
product carries potential risks for the patient including
viral and bacterial transmission, hemolytic transfusionreactions, transfusion related acute lung injury and
immunomodulation and consequently transfusion of
blood products should be reserved to patients who actu-
ally needs this therapy [99].
Hemostatic agents
Antifibrinolytics
Hyperfibrinolysis contribute significantly to coagulopathy
and antifibrinolytics agents reduce the blood loss in patients
with both normal and exaggerated fibrinolytic responses to
surgery by preventing plasmin(ogen) from binding to fibrin
and by preventing plasmin degradation of platelet glycopro-
tein Ib receptors [100,101]. In a placebo controlled rando-
mized study (CRASH-2) including 20,211 adult trauma
patients, tranexamic acid as compared to placebo signifi-
cantly decreased all-cause mortality from 16.0% to 14.5%,
p=0.0035 [102]. We recommend monitoring of hemostasis
with TEG to identify hyperfibrinolytic states in trauma
patients [35-38,65,66] and, consequently, targeted treatment
with antifibrinolytic agents.
Recombinant Factor VIIa
Recombinant factor VIIa (rFVIIa) acts in pharmacological
doses by enhancing thrombin generation on the activated
platelets independent of factor VIII and IX and is cur-
rently approved for episodes of severe hemorrhage or
perioperative management of bleeding in patients with
congenital factor VII deficiency and hemophilia A or B
with inhibitors [103,104]. Data from the CONTROL trial,
a phase 3 randomized clinical trial evaluating efficacy and
safety of rFVIIa as an adjunct to direct hemostasis in
major trauma [105], rFVIIa did not change mortality in
patients with blunt (11.0% (rFVIIa) vs. 10.7% (placebo)) or
penetrating (18.2% (rFVIIa) vs. 13.2% (placebo)) trauma.
[106]In a recent review reporting on the rate of thrombo-
embolic events in all published randomized placebo con-
trolled trials of rFVIIa use [107]reported that the rates of
arterial thromboembolic events among all subjects were
higher among those who received rFVIIa than among
those who received placebo (5.5% vs. 3.2%, p=0.003) [105].
Fibrinogen concentrate
Conversion of sufficient amounts of fibrinogen to fibrin is
a prerequisite for clot formation and reduction in the cir-
culating level of fibrinogen due to consumption [32] and/
or dilution by resuscitation fluids [108] induces coagulopa-
thy [109]. Fibrinogen is the first hemostatic component
that declines to pathologically low levels following trauma
and/or hemodilution [108]. It is, therefore, important to
maintain an adequate fibrinogen level when continued
bleeding is bridged by saline and/or colloid infusion or
blood products (primarily RBC) without fibrinogen. Recent
data indicate that coagulopathy induced by synthetic col-
loids such as HES may be reversed by the administration
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four studies of poor quality assessing fibrinogen concentrate
to bleeding surgical and trauma patients and concluded that
randomized controlled trials of sufficient size and long-term
follow-up needs to be performed before such a practice can
be recommended routinely [111]. The use of fibrinogen con-
centrate in patients with established hypofibrinogenemia,
diagnosed by VHA (Functional FibrinogenW or FibTEMW),
in addition to a balanced administration of RBC, FFP and
platelets, may however contribute to faster achievement of a
normal hemostasis in massively bleeding patients, and we
recommend the use of fibrinogen concentrate according to
TEG guided algorithms in such patients (Table 1).
Prothrombin complex concentrate
The four-factor PCC encompasses coagulation factors II,
VII, IX and X that all are essential for thrombin generation.
Administration of PCC is indicated for the treatment of
congenital coagulation disorders and to reverse oral admi-
nistered anticoagulation by vitamin K antagonists [112],
whereas experience with treatment of massive bleeding
with PCC is lacking. Recently, Carvalho et al. reported that
administration of PCC to patients with massive bleedings
had beneficial effect on hemostasis and this warrants fur-
ther investigation in a randomized controlled setting [113].
Factor XIII
Factor XIII is important for clot firmness by binding to
platelets through the GPIIb/IIIa receptor and by cross-
linking fibrin and increasing the resistance of the formed
clot against fibrinolysis [114]. Notably, patients with “un-
explained” intraoperative coagulopathies and, hence,
bleeding demonstrate significantly less FXIII per unit
thrombin available both before, during and after surgery
[115]. An increased tendency to postoperative bleeding
has been observed, even at factor XIII activities as high
as 60% [116]. The role of FXIII administration to bleed-
ing trauma patients however remains to be investigated
in randomized clinical trials.
Teragnostic approach
Recently, a new approach to resuscitation of patients with
massive blood loss was introduced, employing goal-directed
administration of pharmacological agents such as fibrino-
gen concentrate, prothrombin complex concentrate, recom-
binant factor VIIa and factor XIII as alternatives to FFP and
platelet concentrates together with volume resuscitation
with synthetic colloids. Observational studies of limited size
of such an approach in injured patients with massive blood
loss indicate that it may be feasible to achieve hemostasis
with the use of these procoagulant agents [117].
It should be noted, however, and especially in the light of
the disappointing results from the trial regarding the use of
recombinant factor VII in trauma, that adequately powereddouble-blind randomized studies are required before rou-
tine use of goal-directed administration of procoagulant
agents to injured patients with bleeding is recommended.
This is especially important with regard to the safety of
these agents, which, as opposed to FFP, do not contain
relevant concentrations of natural anticoagulant factors
such as antithrombin, protein C and protein S, and this
may be of importance in the later phase after hemostatic
control has been established [118].
Additionally, it remains elusive which fluid that should
be used to support the hemodynamic system during
massive bleeding treated with the teragnostic approach
when plasma not is included in the resuscitation regi-
men. Crystalloids clearly have not sufficient volume
expanding effects and based on the findings of increased
bleeding, transfusion requirements and mortality in sep-
tic patients receiving synthetic colloids [119] it could be
feared that similar results would surfer in severely
injured trauma patients.
Conclusions
Viscoelastic whole blood assays, such as TEG and ROTEM
are advantageous for identifying coagulopathy, and guide
ongoing transfusion therapy. From the result of these
assays, implementation of a hemostatic control resuscita-
tion strategy to massively bleeding patients seems both rea-
sonable and lifesaving although data from prospective
randomized controlled trials are lacking. Until definite
proof from such trials is available, retrospective data sup-
port a shift in transfusion medicine in regard to early and
aggressive administration of plasma and platelets.
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